Literature DB >> 2341276

Tissue distribution of 131I radiolabeled transferrin in the athymic nude mouse: localization of a human colon adenocarcinoma HT-29 xenograft.

A C Prost1, M Anakök, A Aurengo, J C Salomon, J C Legrand, G Rosselin.   

Abstract

The tissue distribution of 131I-transferrin (131I-Tf) was studied in athymic nude mice having s.c. human colonic adenocarcinoma HT-29 xenografts. Four days after 131I-Tf injection, the 131I-specific activity measured in the HT-29 tumor, i.e. amount of radioactivity per gram of fresh tissue, represented 0.31 +/- 0.09% of the injected radioactivity and was 1.90 fold more than that measured in the murine colon (P less than 0.05). After correction for intravascular 131I-Tf as estimated by means of 99mTc-Sn in vivo labeling of red blood cells, the 131I specific activity observed in the HT-29 tumor was 7.21 fold more than that observed in the murine colon. This subtracting method enabled us to localize a HT-29 tumor xenograft by gamma scintigraphy of the entire animal and demonstrated that 131I-Tf could be a non-specific but potent marker for human colon cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341276     DOI: 10.1016/0883-2897(90)90149-u

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  3 in total

1.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

2.  Annotating MYC status with 89Zr-transferrin imaging.

Authors:  Jason P Holland; Michael J Evans; Samuel L Rice; John Wongvipat; Charles L Sawyers; Jason S Lewis
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

3.  Non-invasive in vivo imaging of near infrared-labeled transferrin in breast cancer cells and tumors using fluorescence lifetime FRET.

Authors:  Ken Abe; Lingling Zhao; Ammasi Periasamy; Xavier Intes; Margarida Barroso
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.